• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Product Image

TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules.

There are today 288 companies plus partners developing 403 TGF-beta receptor pathway targeting drugs in 1356 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 222 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 230 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 222 out of the 225 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 52 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?
- Show investors/board/management that READ MORE >



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos